ECEESPE2025 Poster Presentations MTEabolism, Nutrition and Obesity (125 abstracts)
Real-world outcomes of liraglutide treatment in children with obesity: beyond weight loss
Katarina Štajer1, 2, Jasna Suput Omladic1, 2, Tadej Battelino1, 2 & Primož Kotnik1, 2
1University Children’s Hospital, University Medical Centre Ljubljana, Department of Endocrinology, Diabetes, and Metabolic Diseases, Ljubljana, Slovenia; 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
JOINT888
Background: Liraglutide is a glucagon-like peptide-1 receptor agonist used for pharmacological treatment of children with obesity.
Objective: To evaluate the effects of liraglutide treatment on anthropometric measures, body composition, and metabolic parameters in children with obesity.
Methods: This cohort study analyzed real-world clinical data from children with obesity in Slovenia who were treated with liraglutide between June 2022 and December 2024. The primary outcome measures included changes in anthropometric measurements, body composition, and metabolic parameters over six months.
Results: 31 patients (13 males) had completed six months of liraglutide treatment. The average age at treatment initiation was 15. 56 ± 1. 59 years. The main outcome measures are presented in Table 1. The average loss of body mass was -5. 34 ± 6. 41% (-5. 66 ± 7. 28 kg) and the average reduction of BMI was 6. 10 ± 5. 64%. Children were assigned to 4 categories according to the percentage of body mass reduction: 8 patients lost less than 5%, 7 patients lost 5-10%, 8 patients lost above 10% and 8 patients showed no reduction in body mass after 6 months of treatment.
| Month 0 Average ± SD | Month 6 Average ± SD | p value | |
| Body mass | 115. 09 ± 23. 65 kg | 109. 43 ± 26. 26 kg | 0. 38 |
| Body mass SDS | +3. 97 | +3. 57 | 0. 11 |
| BMI | 39. 46 ± 5. 84 kg/m2 | 37. 15 ± 6. 55 kg/m2 | 0. 15 |
| BMI SDS | +3. 50 | +3. 22 | 0. 05 |
| Waist-to-height ratio | 0. 73 ± 0. 09 (n = 18) | 0. 69 ± 0. 07 (n = 21) | 0. 09 |
| Bioimpedance – body fat | 46. 41 ± 5. 42% (n = 22) | 42. 48 ± 5. 66% (n = 17) | 0. 04 |
| Bioimpedance – skeletal muscle mass | 33. 56 ± 6. 99 kg (n = 22) | 34. 45 ± 8. 46 (n = 17) | 0. 72 |
| Densitometry – body fat | 47. 61 ± 4. 44% (n = 15) | 43. 98 ± 5. 30% (n = 21) | 0. 03 |
| Densitometry – lean muscle mass | 57. 26 ± 13. 26 kg (n = 15) | 59. 61 ± 12. 66 (n = 21) | 0. 60 |
| HOMA-IR | 5. 35 ± 2. 95 (n = 25) | 3. 76 ± 2. 50 (n = 27) | 0. 13 |
| TyG index | 4. 48 ± 0. 21 (n = 24) | 4. 40 ± 0. 23 (n = 28) | 0. 19 |
Conclusions: Liraglutide treatment led to a significant reduction in body fat percentage while preserving skeletal muscle mass. However, metabolic parameters did not show significant improvement after six months.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more